Genmab — April 2017
-
Min triggerliste: 1) 18. april JNJ regnskab. 2) 10.maj Genmab regnskab. 3) 17. maj Janssen Pharmaceutical Business Review. 4) 2-6 juni ASCO. 5) 17. juni PDUFA date dara/pom/dex. 6) H2 ALCYONE front line data. 7) H2 tisotumab vedotin data.
H2 DR5/DR5 + CD3/CD20 i klinikken. 9) og i løbet af 2017 en eller to nye techaftaler (ønsketæbkning). -
Jeg har sikkert glemt noget. Men det er hvad jeg lige kan komme i tanker om
-
Brokers have to sell stocks, financial journalists have to sell papers. It is what it is. Here another one http://www.affarsvarlden.se/bors-ekonominyheter/riskerna-for-hoga-i-genmab-6838745?utm_source=dlvr.it&utm_medium=twitter#conversion-1538946603 Offcourse, they never write these articles at the top, only after a fall
-
Herlig information
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind